Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability)
To ensure safe and effective treatment, it's crucial to have open communication with your healthcare provider, providing them with a comprehensive understanding of your medical history and current medications
While the exact mechanisms remain unclear, several factors are implicated, including nutritional aspects, mechanical unloading, loss of lean mass, and alterations in the secretion of gut hormones and adipokines [8, 10]
His employer receives research funding from Dexcom, Eli Lilly, NovaTarg, Novo Nordisk, Sanofi, Tolerion and vTv Therapeutics